InsiderTrades.com logo
David R. Ebsworth net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

David Ebsworth Biography and Net Worth

Director of Verona Pharma PLC American Depositary Share
Dr Ebsworth has significant experience in leadership and management of pharma and biotech companies internationally. Dr Ebsworth currently serves on the boards of Sartorius and Synlab. From October 2009 to August 2014, Dr Ebsworth served as Chief Executive Officer of Vifor Pharma, based in Zürich, the specialty pharma division of Galenica AG Group, a pharmaceutical wholesaler and retailer, and as a member of Galenica’s Executive Committee. In 2012, Dr Ebsworth was also named as Chief Executive Officer of Galenica and as Chairman of Galenica’s Executive Committee, positions he held until August 2014. In his earlier career, Dr Ebsworth worked with Bayer for over 19 years, heading the Canadian, North American and global pharmaceutical business. Dr Ebsworth received a PhD in industrial relations from the University of Surrey.

What is David R. Ebsworth's net worth?

The estimated net worth of David R. Ebsworth is at least $94.13 million as of August 1st, 2025. Dr. Ebsworth owns 880,499 shares of Verona Pharma PLC American Depositary Share stock worth more than $94,134,148 as of December 5th. This net worth evaluation does not reflect any other investments that Dr. Ebsworth may own. Learn More about David R. Ebsworth's net worth.

How do I contact David R. Ebsworth?

The corporate mailing address for Dr. Ebsworth and other Verona Pharma PLC American Depositary Share executives is 3 MORE LONDON RIVERSIDE, LONDON X0, SE1 2RE. Verona Pharma PLC American Depositary Share can also be reached via phone at 011-44-0-2032834200 and via email at [email protected]. Learn More on David R. Ebsworth's contact information.

Has David R. Ebsworth been buying or selling shares of Verona Pharma PLC American Depositary Share?

David R. Ebsworth has not been actively trading shares of Verona Pharma PLC American Depositary Share during the last ninety days. Most recently, David R. Ebsworth sold 1,904 shares of the business's stock in a transaction on Friday, August 1st. The shares were sold at an average price of $13.14, for a transaction totalling $25,018.56. Following the completion of the sale, the director now directly owns 880,499 shares of the company's stock, valued at $11,569,756.86. Learn More on David R. Ebsworth's trading history.

Who are Verona Pharma PLC American Depositary Share's active insiders?

Verona Pharma PLC American Depositary Share's insider roster includes Christina Ackermann (Director), Michael Austwick (Director), James Brady (Director), Kenneth Cunningham (Director), Lisa Deschamps (Director), David Ebsworth (Director), Martin Edwards (Director), Patrick Finn (Insider), Andrew Fisher (General Counsel), Mark Hahn (CFO), Claire Poll (General Counsel), Kathleen Rickard (Insider), Mahendra Shah (Director), Vikas Sinha (Director), Anders Ullman (Director), and David Zaccardelli (CEO). Learn More on Verona Pharma PLC American Depositary Share's active insiders.

Are insiders buying or selling shares of Verona Pharma PLC American Depositary Share?

In the last year, insiders at the sold shares 30 times. They sold a total of 2,932,176 shares worth more than $29,558,114.16. The most recent insider tranaction occured on August, 1st when Director Kenneth Cunningham sold 10,808 shares worth more than $142,017.12. Insiders at Verona Pharma PLC American Depositary Share own 4.8% of the company. Learn More about insider trades at Verona Pharma PLC American Depositary Share.

Information on this page was last updated on 8/1/2025.

David R. Ebsworth Insider Trading History at Verona Pharma PLC American Depositary Share

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/1/2025Sell1,904$13.14$25,018.56880,499View SEC Filing Icon  
11/6/2024Buy39,360$4.80$188,928.00920,003View SEC Filing Icon  
11/6/2023Buy160,000$1.98$316,800.00844,643View SEC Filing Icon  
See Full Table

David R. Ebsworth Buying and Selling Activity at Verona Pharma PLC American Depositary Share

This chart shows David R Ebsworth's buying and selling at Verona Pharma PLC American Depositary Share by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Verona Pharma PLC American Depositary Share Company Overview

Verona Pharma PLC American Depositary Share logo
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.
Read More

Today's Range

Now: $106.91
Low: $106.91
High: $106.91

50 Day Range

MA: $106.65
Low: $105.91
High: $106.95

2 Week Range

Now: $106.91
Low: $31.09
High: $106.93

Volume

N/A

Average Volume

1,457,608 shs

Market Capitalization

$9.21 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.05